How to Give More Without Causing Heart Failure* Richard Solomon, MD I odinated contrast media is widely used to enhance the image of organs and the vascular compartment. In a small percentage of patients, the administration of contrast is followed by a decrease in glomerular filtration rate (GFR), referred to as contrast-induced nephropathy (CIN). The fall in GFR is detected by a rise in serum creatinine evident within 48 to 72 h of contrast exposure. The decrement in GFR is usually transient, and serum creatinine returns to or near baseline levels within 7 to 10 days.
CIN is, nevertheless, associated with in-hospital mortality and adverse events (1), long-term mortality (2), progression of kidney disease (3), long-term major adverse cardiovascular events (4) , and reduced use of cardiovascular preventative medications (5).
The mechanism of CIN is multifactorial and includes regional hemodynamic changes (6) as well as direct renal tubule cell toxicity (7) . Patients at risk for CIN are usually older, receive more contrast, and have underlying compromised kidney and vascular function (chronic kidney disease, diabetes, heart failure).
The setting in which contrast is administered is also 
heart failure (ADHF). It is this goal to achieve efficacy without sacrifice of safety that drives attempts to find novel ways to guide therapy. 
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